Journals / Türk Klinik Biyokimya Dergisi / 2019 / Cilt: 17 - Sayı: 3
Ischemia Modified Albumin Levels in Invasive Ductal Carcinoma and Fibroadenoma Patients
- Pages
- 134–139
- DOI
- —
Abstract
Aim: Chronic kidney disease (CKD) is highly prevalent, with increasing numbers of patients affected by the disease world-wide (1). Anemia is a common complica- tion that contributes to the burden of disease associated with CK D, and it impacts negatively on cardiovascular disease, exercise capacity, and quality of life, resulting in significant mortality and morbidity in patients with CKD (2–5). Anemia iscurrently defined by the World Health Organization (WHO) as a hemoglobin (Hb) level o13 g/dL in men and o12 g/dL in women (6).Purpose: Impaired oxidative-antioxidative balance plays an important role in the pathogenesis of many diseases like cancer. Ischemia modified albumin (IMA) is altered albumin by free radicals generated from ischemic tissues. The aim of this study was to evaluate the levels of the IMA in newly diagnosed patients with invasive ductal carcinoma and fibroadenoma before the surgery or medical treatment.Methods: IMA levels were measured in 30 patients which were diagnosed as “invasive ductal carcinoma’’(Group 1), 30 patients as “fibroadenoma’’(Group 2) and in 28 “healthy controls’’(Group 3). An albumin-cobalt binding test was used to define serum IMA in absorbance units (ABSU).Results: There were statistically significant differences between three groups. IMA levels were significantly higher in the invasive ductal carcinoma group (0.434±0.056 ABSU) compared to fibroadenoma group (0.344±0.135 ABSU) and control group (0.196±0.050 ABSU) (p
Özet
Amaç:Bozulmuş oksidatif-antioksidan denge, kanser gibi birçok hastalığın patogenezinde önemli bir rol oynar. İskemi modifiye albümin (IMA), iskemik dokulardan üretilen serbest radikallerle değişime uğramış albümindir. Bu çalışmanın amacı, invaziv duktal karsinomlu ve fibroadenomlu yeni tanı alan hastalarda cerrahi veya medikal tedavi öncesi IMA düzeylerini değerlendirmektir.Gereç ve Yöntem: IMA düzeyleri invaziv duktal karsinom tanısı alan 30 hastada (Grup 1), fibroadenom tanısı alan 30 hastada (Grup 2) ve 28 sağlıklı kontrol grubunda (Grup 3) ölçüldü. Serum IMAdüzeyleri albümin-kobalt bağlanma testi ile absorbans ünitesi (ABSU) olarak ölçüldü.Bulgular: Üç grup arasında istatistiksel olarak anlamlı fark vardı. IMA düzeyleri invaziv duktal karsinom grubunda (0.434 ± 0.056 ABSU) fibroadenoma grubuna (0.344 ± 0.135 ABSU) ve kontrol grubuna (0.196 ± 0.050 ABSU) göre anlamlı derecede yüksekti (p